- Home
- VMET vs OPK Comparison
VMET vs OPK Comparison
Compare VMET & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VMET | OPK |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | Canada | United States |
| Employees | 8 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 921.2M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | VMET | OPK |
|---|---|---|
| Price | $12.64 | $1.20 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $1.55 |
| AVG Volume (30 Days) | 209.2K | ★ 1.8M |
| Earning Date | 05-13-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $606,879,000.00 |
| Revenue This Year | $185.47 | N/A |
| Revenue Next Year | $16.05 | $4.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.10 | $1.10 |
| 52 Week High | $13.73 | $1.60 |
Technical Indicators
Market Signals| Indicator | VMET | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 56.95 | 51.99 |
| Support Level | $11.00 | $1.12 |
| Resistance Level | $13.73 | $1.22 |
| Average True Range (ATR) | 0.68 | 0.04 |
| MACD | 0.12 | 0.00 |
| Stochastic Oscillator | 58.97 | 50.00 |
Price Performance
Historical ComparisonAbout VMET Versamet Royalties Corporation Common Stock
Versamet Royalties Corp is a diversified metals royalty and streaming company with exposure to a range of resource royalties and streams including gold, silver, copper, zinc, graphite and uranium, across a variety of jurisdictions. The Company's operating segments are considered to be its individual royalties, streams and the Greenstone gold interest.
About OPK OPKO Health Inc.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.